- Natural Supplement for Attention-Deficit Hyperactivity Disorder in
Children Fulfills Growing Need Throughout Asia -
NEW HAVEN, Conn. and KORTRIJK, Belgium, Feb. 19 /PRNewswire/ -- RHEI Pharmaceuticals, Inc., a fully integrated specialty pharmaceuticals company focused on bringing proprietary medicines to the China market, and MethaPharma, part of then Vemedia Group, today announced that RHEI has licensed from MethaPharma the exclusive right to market and distribute Attental(R) throughout Asia. Attental is a nutraceutical currently commercially available in Europe for attention-deficit hyperactivity disorder (ADHD) in children.
"There is a great opportunity for Attental throughout Asia where parents prefer giving their children natural products versus prescription drugs," said Joos Horsten, Executive Chairman and Chief Executive Officer of RHEI. "There has been a growing awareness of ADHD in Asia as a more western diet and lifestyle is adopted. In addition, there are now several government programs in place to train doctors and teachers to better identify and treat children suffering from ADHD. RHEI will utilize its experience in pharmaceutical marketing and its network of contacts, particularly within the pediatric community, to bring this important natural remedy to the Asian market."
Attental has been proven in a randomized, double-blind, placebo controlled clinical trial to better overall motor performance and improve reading and spelling in children. The clinical trial demonstrated a significant improvement in the Conners' Teaching Rating Scale-L (CTRS-L) of 59 items describing different aspects of child behavior, as well as in the Child Behavior Checklist (CBCL) -- standard evaluation methods for ADHD.
"RHEI's approach which includes a hospital-based sales force in China
that understands the scientific aspects of ADHD and can communicate the
benefits of Attental, combined with their experience in direct to co
'/>"/>
| SOURCE RHEI Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |